CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activityIn VitroCPI-1612 inhibits full length EP300 and full length CBP with IC 50
Applications:A potent and selective agonist of the putative, excitatory neurotransmitter L-glutamic acid. AMPA does not interfere with binding sites for kainic acid in vitro, and AMPA- induced neuronal excitation is not significantly affected by
Applications:A potent and selective agonist of the putative, excitatory neurotransmitter L-glutamic acid. AMPA does not interfere with binding sites for kainic acid in vitro, and AMPA- induced neuronal excitation is not significantly affected by
This certified reference material (CRM) is produced and certified in accordance with ISO/IEC 17025 and ISO 17034 . This CRM is traceable to primary material from an NMI, e.
This certified reference material (CRM) is produced and certified in accordance with ISO/IEC 17025 and ISO 17034 . This CRM is traceable to primary material from an NMI, e.